Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668567 | 0.92 | TACR3 (0.37) | TACR3KDM4EALDH1A1L3MBTL1TSHR | |
| SCHEMBL4668577 | 0.89 | TACR3 (0.36) | TACR3KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4665274 | 0.86 | TACR3 (0.45) | TACR3KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4667074 | 0.85 | TACR3 (0.53) | TACR3KCNH2KDM4EALDH1A1TSHR | |
| SCHEMBL4668628 | 0.79 | LMNA (0.49) | TACR3KCNH2ALDH1A1TACR2 | |
| SCHEMBL5004648 | 0.79 | TACR3 (0.39) | TACR3KCNH2TACR2 | |
| SCHEMBL4667068 | 0.78 | TACR3 (0.41) | TACR3KCNH2TACR2 | |
| SCHEMBL4665272 | 0.77 | TSHR (0.47) | TACR3KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4665277 | 0.77 | TSHR (0.46) | TACR3KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4665876 | 0.75 | TACR3 (0.40) | TACR3KCNH2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |